Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New heart zapping tech tested for stubborn AFib

NCT ID NCT05408754

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two new devices that use energy pulses to treat persistent atrial fibrillation (a type of irregular heartbeat). 89 adults who had not responded to medication received a heart ablation procedure. The goal was to see if the devices are safe and can stop abnormal heart rhythms for at least a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pulsed field ablation and pulsed field cryoablation systems (devices that use energy to destroy heart tissue causing abnormal rhythms)
What this could lead to
If successful, this could provide a safer, more effective way to treat persistent atrial fibrillation, potentially reducing the need for long-term medication.
What could go wrong
This is an early, first-in-human study with only 89 participants, so results may not apply to everyone. There are risks of procedure-related complications like bleeding or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

89 people

The number who actually took part.

Started

Oct 2022

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: IC 1 Male or female between the ages of 18 - 80 years IC 2 Currently scheduled for an ablation of symptomatic persistent (\> 7 days) atrial fibrillation within the past year documented by ECG or Continuous Holter monitoring IC 3 Refractory to at least one class I or III AAD. (Refractory defined as not effective or not tolerated) IC 4 Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study IC 5 Willingness and ability to give an informed consent Exclusion Criteria: EC 1 In the opinion of the Investigator, any known contraindication to an atrial ablation, TEE, or anticoagulation. Including but not limited to the identification of any atrial thrombus or evidence of sepsis EC 2 Continuous AF lasting longer than 12-months EC 3 History of previous left atrial ablation or surgical treatment for AF/AFL/AT EC 4 AF secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause EC 5 Structural heart disease as described below: 1. Left ventricular ejection fraction (LVEF) \< 40% based on most recent TTE 2. Left atrial size \> 55 mm (parasternal long axis view) documented within 6-months of screening 3. NYHA Class III or IV heart failure documented within the previous 12-months 4. An implanted pacemaker or ICD 5. Previous cardiac surgery, ventriculotomy, or atriotomy (excluding atriotomy for CABG), 6. Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve 7. Interatrial baffle, closure device, patch, or PFO occluder 8. Presence of a left atrial appendage occlusion device 9. Presence of any pulmonary vein stenting devices 10. Coronary artery bypass graft (CABG) or PTCA procedure within six (6) months prior to procedure 11. Unstable angina or ongoing myocardial ischemia 12. Myocardial infarction within the previous six (6) months prior to procedure 13. Moderate or severe mitral insufficiency or stenosis based on most recent TTE 14. Atrial myxoma 15. Significant congenital anomaly EC 6 BMI \> 40 EC 7 Any previous history of cryoglobulinemia (for those patients randomized to the PFCA arm) EC 8 History of blood clotting or bleeding disease EC 9 History of severe COPD requiring steroid use in the previous 12-months EC 10 History of severe sleep apnea (AHI \> 30) not currently treated with a CPAP machine or other mechanical device EC 11 Stroke or TIA within the last year. EC 12 Any prior history or current evidence of hemidiaphragmatic paralysis EC 13 Pregnant or lactating (current or anticipated during study follow-up EC 14 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study EC 15 Any other conditions such as, mental illness, addictive disease, terminal illness with a life expectancy of less than two years, extensive travel away from the research center that may lead to non-compliance with the protocol procedure or follow up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Blackrock Health

    Dublin, A94 E4X7, Ireland

  • McGill University Health Centre (MUHC), Montreal General Hospital (MGH)

    Montreal, Quebec, H3G 1A4, Canada

  • Nemocnice Na Homolce

    Prague, 150 30, Czechia

  • Onze-Lieve-Vrouwziekenhuis (OLV)

    Aalst, B-9300, Belgium

  • St Antonius Ziekenhuis

    Nieuwegein, 3435, Netherlands

  • St George'S University Hospital

    London, SW17 0QT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.